The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

benzothiole     benzothiophene

Synonyms: Thianaphtene, Thianaphthen, Benzothiophen, Thianaphthene, Thionaphthene, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of benzothiophene

  • Though structurally unrelated to chrysin, an HIV-1 inhibitory benzothiophene also bound selectively to CKII [1].
  • PURPOSE: We conducted this phase I trial to determine the safety and toxicity profile of LY353381.HCl-a novel, potent, third-generation selective estrogen receptor modulator (SERM)-because this benzothiophene derivative demonstrated an SERM profile in preclinical studies [2].
  • Biodesulfurization of naphthothiophene and benzothiophene through selective cleavage of carbon-sulfur bonds by Rhodococcus sp. strain WU-K2R [3].
  • Isopropylbenzene-degrading bacteria, including Pseudomonas putida RE204, transform benzothiophene to a mixture of compounds [4].
  • MATERIALS AND METHODS: Cellular models of latent (OM-10.1 and U1) and chronic (8E5) HIV infection were used to evaluate two benzothiophene derivatives, PD 121871 and PD 144795, for an ability to inhibit HIV activation and expression [5].

High impact information on benzothiophene


Chemical compound and disease context of benzothiophene


Biological context of benzothiophene


Anatomical context of benzothiophene


Associations of benzothiophene with other chemical compounds


Gene context of benzothiophene


Analytical, diagnostic and therapeutic context of benzothiophene


  1. Casein kinase II is a selective target of HIV-1 transcriptional inhibitors. Critchfield, J.W., Coligan, J.E., Folks, T.M., Butera, S.T. Proc. Natl. Acad. Sci. U.S.A. (1997) [Pubmed]
  2. Phase I study of a third-generation selective estrogen receptor modulator, LY353381.HCL, in metastatic breast cancer. Münster, P.N., Buzdar, A., Dhingra, K., Enas, N., Ni, L., Major, M., Melemed, A., Seidman, A., Booser, D., Theriault, R., Norton, L., Hudis, C. J. Clin. Oncol. (2001) [Pubmed]
  3. Biodesulfurization of naphthothiophene and benzothiophene through selective cleavage of carbon-sulfur bonds by Rhodococcus sp. strain WU-K2R. Kirimura, K., Furuya, T., Sato, R., Ishii, Y., Kino, K., Usami, S. Appl. Environ. Microbiol. (2002) [Pubmed]
  4. Biotransformation of benzothiophene by isopropylbenzene-degrading bacteria. Eaton, R.W., Nitterauer, J.D. J. Bacteriol. (1994) [Pubmed]
  5. Compounds that target novel cellular components involved in HIV-1 transcription. Butera, S.T., Roberts, B.D., Critchfield, J.W., Fang, G., McQuade, T., Gracheck, S.J., Folks, T.M. Mol. Med. (1995) [Pubmed]
  6. Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. Black, L.J., Sato, M., Rowley, E.R., Magee, D.E., Bekele, A., Williams, D.C., Cullinan, G.J., Bendele, R., Kauffman, R.F., Bensch, W.R. J. Clin. Invest. (1994) [Pubmed]
  7. p53 transactivation of the HIV-1 long terminal repeat is blocked by PD 144795, a calcineurin-inhibitor with anti-HIV properties. Gualberto, A., Marquez, G., Carballo, M., Youngblood, G.L., Hunt, S.W., Baldwin, A.S., Sobrino, F. J. Biol. Chem. (1998) [Pubmed]
  8. Future use of selective estrogen receptor modulators and aromatase inhibitors. Howell, A. Clin. Cancer Res. (2001) [Pubmed]
  9. Novel combretastatin analogues endowed with antitumor activity. Simoni, D., Romagnoli, R., Baruchello, R., Rondanin, R., Rizzi, M., Pavani, M.G., Alloatti, D., Giannini, G., Marcellini, M., Riccioni, T., Castorina, M., Guglielmi, M.B., Bucci, F., Carminati, P., Pisano, C. J. Med. Chem. (2006) [Pubmed]
  10. Preparation and characterization of organotin-oxomolybdate coordination polymers and their use in sulfoxidation catalysis. Abrantes, M., Valente, A.A., Pillinger, M., Gonçalves, I.S., Rocha, J., Romão, C.C. Chemistry (Weinheim an der Bergstrasse, Germany) (2003) [Pubmed]
  11. Mineralization of the dibenzothiophene biodegradation products 3-hydroxy-2-formyl benzothiophene and dibenzothiophene sulfone. Mormile, M.R., Atlas, R.M. Appl. Environ. Microbiol. (1988) [Pubmed]
  12. Chemical modification modulates estrogenic activity, oxidative reactivity, and metabolic stability in 4'F-DMA, a new benzothiophene selective estrogen receptor modulator. Liu, H., Bolton, J.L., Thatcher, G.R. Chem. Res. Toxicol. (2006) [Pubmed]
  13. Suppression of polarity, locomotion and F-actin levels of Walker carcinosarcoma cells by the inhibitor CI-959. von Tscharner Biino, N., Porzig, H., Keller, H. Life Sci. (1997) [Pubmed]
  14. LY353381.HCl, a selective estrogen receptor modulator, and experimental stroke. Rossberg, M.I., Murphy, S.J., Traystman, R.J., Hurn, P.D. Stroke (2000) [Pubmed]
  15. Diamino benzo[b]thiophene derivatives as a novel class of active site directed thrombin inhibitors. 5. Potency, efficacy, and pharmacokinetic properties of modified C-3 side chain derivatives. Sall, D.J., Bailey, D.L., Bastian, J.A., Buben, J.A., Chirgadze, N.Y., Clemens-Smith, A.C., Denney, M.L., Fisher, M.J., Giera, D.D., Gifford-Moore, D.S., Harper, R.W., Johnson, L.M., Klimkowski, V.J., Kohn, T.J., Lin, H.S., McCowan, J.R., Palkowitz, A.D., Richett, M.E., Smith, G.F., Snyder, D.W., Takeuchi, K., Toth, J.E., Zhang, M. J. Med. Chem. (2000) [Pubmed]
  16. Inhibitory activity of diarylamidine derivatives on murine leukemia L1210 cell growth. Balzarini, J., de Clercq, E., Dann, O. Investigational new drugs. (1983) [Pubmed]
  17. Cytochrome P450 3A4-mediated bioactivation of raloxifene: irreversible enzyme inhibition and thiol adduct formation. Chen, Q., Ngui, J.S., Doss, G.A., Wang, R.W., Cai, X., DiNinno, F.P., Blizzard, T.A., Hammond, M.L., Stearns, R.A., Evans, D.C., Baillie, T.A., Tang, W. Chem. Res. Toxicol. (2002) [Pubmed]
  18. In vitro metabolic fate of a novel structural class: evidence for the formation of a reactive intermediate on a benzothiophene moiety. Evans, C.A., Fries, H.E., Ward, K.W. Chem. Biol. Interact. (2005) [Pubmed]
  19. Marked suppression of T cells by a benzothiophene derivative in patients with human T-lymphotropic virus type I-associated myelopathy/tropical spastic paraparesis. Makino, M., Azuma, M., Wakamatsu, S.I., Suruga, Y., Izumo, S., Yokoyama, M.M., Baba, M. Clin. Diagn. Lab. Immunol. (1999) [Pubmed]
  20. In vitro bioeffects of the antiestrogen LY117018 on desmoid tumor and colon cancer cells. Picariello, L., Fiorelli, G., Benvenuti, S., Brandi, M.L., Galli, G., Malentacchi, C., Montali, E., Bigozzi, U., Ficari, F., Tonelli, F. Anticancer Res. (1997) [Pubmed]
  21. Effects of benzothiophene on male rats following short-term oral exposure. Poon, R., Davis, H., Lecavalier, P., Liteplo, R., Yagminas, A., Chu, I., Bihun, C. Journal of toxicology and environmental health. (1997) [Pubmed]
  22. Inhibitors of protein kinase C. 1. 2,3-Bisarylmaleimides. Davis, P.D., Hill, C.H., Lawton, G., Nixon, J.S., Wilkinson, S.E., Hurst, S.A., Keech, E., Turner, S.E. J. Med. Chem. (1992) [Pubmed]
  23. One-pot synthesis of benzo[b]furan and indole inhibitors of tubulin polymerization. Flynn, B.L., Hamel, E., Jung, M.K. J. Med. Chem. (2002) [Pubmed]
  24. An improved assay procedure and a new chemically stable ligand for cytosolic retinoic acid binding protein. Gazith, J., Eustache, J., Watts, O., Cavey, M.T., Shroot, B. Anal. Biochem. (1988) [Pubmed]
  25. Ligand-independent and agonist-mediated degradation of estrogen receptor-alpha in breast carcinoma cells: evidence for distinct degradative pathways. Nonclercq, D., Journé, F., Body, J.J., Leclercq, G., Laurent, G. Mol. Cell. Endocrinol. (2004) [Pubmed]
  26. Macrophage inducible nitric oxide synthase gene expression is blocked by a benzothiophene derivative with anti-HIV properties. Carballo, M., Conde, M., Tejedo, J., Gualberto, A., Jimenez, J., Monteseirín, J., Santa María, C., Bedoya, F.J., Hunt, S.W., Pintado, E., Baldwin, A.S., Sobrino, F. Mol. Genet. Metab. (2002) [Pubmed]
  27. Carbonic anhydrase inhibitors: inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with benzo[b]thiophene 1,1-dioxide sulfonamides. Innocenti, A., Villar, R., Martinez-Merino, V., Gil, M.J., Scozzafava, A., Vullo, D., Supuran, C.T. Bioorg. Med. Chem. Lett. (2005) [Pubmed]
  28. Structure-activity relationships of a series of benzothiophene-derived NPY Y1 antagonists: optimization of the C-2 side chain. Britton, T.C., Spinazze, P.G., Hipskind, P.A., Zimmerman, D.M., Zarrinmayeh, H., Schober, D.A., Gehlert, D.R., Bruns, R.F. Bioorg. Med. Chem. Lett. (1999) [Pubmed]
  29. Reversal of resistance in multidrug resistance protein (MRP1)-overexpressing cells by LY329146. Norman, B.H., Dantzig, A.H., Kroin, J.S., Law, K.L., Tabas, L.B., Shepard, R.L., Palkowitz, A.D., Hauser, K.L., Winter, M.A., Sluka, J.P., Starling, J.J. Bioorg. Med. Chem. Lett. (1999) [Pubmed]
  30. Isolation and characterization of thermophilic benzothiophene-degrading Mycobacterium sp. Watanapokasin, Y., Nuchfoang, S., Nilwarangkoon, S., Sarangbin, S., Kakizono, T. Appl. Biochem. Biotechnol. (2002) [Pubmed]
WikiGenes - Universities